Galapagos Receives €3.7 Million Grant for Cystic Fibrosis Program
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Galapagos NV announces that it has been awarded a €3.7 million grant from the Flemish agency for Innovation by Science and Technology (IWT).
The three-year project "Disease-modifying drug discovery in cystic fibrosis" focuses on Galapagos' cystic fibrosis (CF) program based on novel drug targets, with the goal to deliver a pre-clinical candidate. Galapagos will collaborate on this project with the Center for Human Genetics at the KU Leuven.
"Galapagos is breaking new ground in CF with its novel targets. We are pleased that the IWT chooses to support these efforts. The collaboration with the Center for Human Genetics helps us to prioritize the novel targets which could make the most difference to CF patients," said Graham Dixon, SVP Drug Discovery for Galapagos. "This grant increases the chances of delivering a pre-clinical candidate by our target date of 2013."
The three-year project "Disease-modifying drug discovery in cystic fibrosis" focuses on Galapagos' cystic fibrosis (CF) program based on novel drug targets, with the goal to deliver a pre-clinical candidate. Galapagos will collaborate on this project with the Center for Human Genetics at the KU Leuven.
"Galapagos is breaking new ground in CF with its novel targets. We are pleased that the IWT chooses to support these efforts. The collaboration with the Center for Human Genetics helps us to prioritize the novel targets which could make the most difference to CF patients," said Graham Dixon, SVP Drug Discovery for Galapagos. "This grant increases the chances of delivering a pre-clinical candidate by our target date of 2013."
